(S (NP (NP (NNP Predicting) (NN response)) (PP (IN to) (NP (NN neoadjuvant) (NN therapy)))) (VP (VBZ is) (NP (NP (DT a) (JJ vexing) (NN challenge)) (PP (IN in) (NP (NN breast) (NN cancer))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP evaluate) (SBAR (S (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (JJ deep) (NN learning))) (S (VP (TO to) (VP (VB predict) (NP (NN response)) (PP (IN to) (NP (NP (ADJP (NP (NN HER2)) (HYPH -) (VBN targeted)) (JJ neo-adjuvant) (NN chemotherapy) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-))) (PP (IN from) (NP (ADJP (NP (JJ pre-treatment) (JJ dynamic) (NN contrast)) (HYPH -) (VBN enhanced)) (NML (NML (-LRB- -LRB-) (NNP DCE) (-RRB- -RRB-)) (NNP MRI)))))))))) (VP (VBD acquired) (PP (JJ prior) (PP (IN to) (NP (NN treatment)))))))) (. .))
(S (PP (IN In) (NP (NP (DT a) (JJ retrospective) (NN study)) (VP (VBG encompassing) (NP (NML (NNP DCE) (HYPH -) (NNP MRI)) (NNS data)) (PP (IN from) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 157) (NML (NN HER2) (SYM +) (NN breast)) (NN cancer) (NNS patients)) (PP (IN from) (NP (CD 5) (NNS institutions)))))))))) (, ,) (NP (PRP we)) (VP (VBD developed) (CC and) (VBD validated) (NP (NP (DT a) (NML (JJ deep) (NN learning)) (NN approach)) (PP (IN for) (S (VP (VBG predicting) (NP (NP (JJ pathological) (JJ complete) (NN response)) (-LRB- -LRB-) (NP (NN pCR)) (-RRB- -RRB-)) (PP (IN to) (NP (NP (ADJP (NP (NN HER2)) (HYPH -) (VBN targeted)) (NN NAC)) (PP (JJ prior) (IN to) (NP (NN treatment)))))))))) (. .))
(S (S (NP (NP (CD 100) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (ADJP (NP (NN HER2)) (HYPH -) (VBN targeted)) (JJ neoadjuvant) (NN chemotherapy)) (PP (IN at) (NP (DT a) (JJ single) (NN institution))))))) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB train)))) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (SYM =) (NP (CD 85)))) (-RRB- -RRB-))))) (CC and) (S (NP (NP (NN tune) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (SYM =) (NP (CD 15)))) (-RRB- -RRB-))) (NP (NP (DT a) (JJ convolutional) (JJ neural) (NN network)) (-LRB- -LRB-) (NP (NNP CNN)) (-RRB- -RRB-))) (VP (TO to) (VP (VB predict) (NP (NN pCR))))) (. .))
(S (NP (NP (DT A) (JJ multi-input) (NNP CNN)) (VP (VBG leveraging) (NP (DT both) (ADJP (JJ pre-contrast) (CC and) (JJ late)) (JJ post-contrast) (NML (NNP DCE) (HYPH -) (NNP MRI)) (NNS acquisitions)))) (VP (VBD was) (VP (VBN identified) (S (VP (TO to) (VP (VB achieve) (NP (JJ optimal) (NN response) (NN prediction)) (PP (IN within) (NP (DT the) (NN validation) (NN set)))))) (PRN (-LRB- -LRB-) (S (NP (NN AUC)) (VP (SYM =) (NP (CD 0.93)))) (-RRB- -RRB-)))) (. .))
(S (NP (DT This) (NN model)) (VP (VBD was) (ADVP (RB then)) (VP (VBN tested) (PP (IN on) (NP (NP (CD two) (JJ independent) (NN testing) (NNS cohorts)) (PP (IN with) (NP (JJ pre-treatment) (NML (NNP DCE) (HYPH -) (NNP MRI)) (NNS data))))))) (. .))
(S (NP (PRP It)) (VP (VBD achieved) (NP (NP (JJ strong) (NN performance)) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 28) (JJ patient)) (NN testing)) (VP (VBN set) (PP (IN from) (NP (DT a) (JJ second) (NN institution))) (PRN (-LRB- -LRB-) (S (NP (NN AUC)) (VP (SYM =) (NP (NML (NML (CD 0.85)) (, ,) (NML (CD 95) (NN %))) (NN CI) (CD 0.67) (HYPH -) (CD 1.0)))) (, ,) (S (NP (NN p)) (VP (SYM =) (NP (CD .0008)))) (-RRB- -RRB-)))) (CC and) (NP (NP (DT a) (NML (CD 29) (NN patient)) (NN multicenter) (NN trial)) (PP (VBG including) (NP (NP (NNS data)) (PP (IN from) (NP (CD 3) (JJ additional) (NNS institutions))))))))) (PRN (-LRB- -LRB-) (S (NP (NN AUC)) (VP (SYM =) (NP (NML (QP (CD 0.77) (, ,) (CD 95)) (NN %)) (NN CI) (CD 0.58) (HYPH -) (CD 0.97)))) (, ,) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.006)))) (-RRB- -RRB-))) (. .))
(S (NP (ADJP (NP (JJ Deep) (NN learning)) (HYPH -) (VBN based)) (NN response) (NN prediction) (NN model)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB exceed) (NP (DT a) (JJ multivariable) (NN model)) (S (VP (VBG incorporating) (NP (NP (JJ predictive) (JJ clinical) (NNS variables) (PRN (-LRB- -LRB-) (S (NP (NN AUC)) (VP (SYM <) (NP (NP (CD .65)) (PP (IN in) (NP (NN testing) (NNS cohorts)))))) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ semi-quantitative) (NML (NNP DCE) (HYPH -) (NNP MRI)) (JJ pharmacokinetic) (NNS measurements)))))))))) (PRN (-LRB- -LRB-) (S (NP (NN AUC)) (VP (SYM <) (NP (NP (CD .60)) (PP (IN in) (NP (NN testing) (NNS cohorts)))))) (-RRB- -RRB-)))) (. .))
(S (NP (NP (DT The) (NNS results)) (VP (VBN presented) (PP (IN in) (NP (NP (DT this) (NN work)) (PP (IN across) (NP (JJ multiple) (NNS sites))))))) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN with) (NP (JJ further) (NN validation))) (NP (JJ deep) (NN learning)) (VP (MD could) (VP (VB provide) (NP (DT an) (ADJP (JJ effective) (CC and) (JJ reliable)) (NN tool)) (S (VP (TO to) (VP (VB guide) (NP (VBN targeted) (NN therapy)) (PP (IN in) (NP (NN breast) (NN cancer))) (, ,) (S (ADVP (RB thus)) (VP (VBG reducing) (NP (NN overtreatment)) (PP (IN among) (NP (NML (NN HER2) (SYM +)) (NNS patients))))))))))))) (. .))
